Lyell Immunopharma Inc (NASDAQ:LYEL) has a beta value of -0.48 and has seen 1.97 million shares traded in the last trading session. The company, currently valued at $334.40M, closed the last trade at $1.12 per share which meant it gained $0.16 on the day or 16.63% during that session. The LYEL stock price is -191.07% off its 52-week high price of $3.26 and 24.11% above the 52-week low of $0.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.01 million shares traded. The 3-month trading volume is 999.12K shares.
The consensus among analysts is that Lyell Immunopharma Inc (LYEL) is Hold stock at the moment, with a recommendation rating of 3.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 3 out of 3 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.2.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
Sporting 16.63% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the LYEL stock price touched $1.12 or saw a rise of 5.08%. Year-to-date, Lyell Immunopharma Inc shares have moved -42.27%, while the 5-day performance has seen it change 20.82%. Over the past 30 days, the shares of Lyell Immunopharma Inc (NASDAQ:LYEL) have changed -5.88%. Short interest in the company has seen 10.76 million shares shorted with days to cover at 13.91.
Wall Street analysts have a consensus price target for the stock at $7, which means that the shares’ value could jump 84.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $12.0. In that case, then, we find that the current price level is -971.43% off the targeted high while a plunge would see the stock lose 10.71% from current levels.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
Figures show that Lyell Immunopharma Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -52.54% over the past 6 months, with this year growth rate of 8.60%, compared to 18.30% for the industry. Revenue growth from the last financial year stood is estimated to be -92.30%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -15.28% over the past 5 years. Earnings growth for 2024 is a modest 9.95% while over the next 5 years, the company’s earnings are expected to decrease by -7.90%.
LYEL Dividends
Lyell Immunopharma Inc is expected to release its next earnings report on 2024-Aug-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Insiders own 13.35% of the company shares, while shares held by institutions stand at 60.22% with a share float percentage of 69.50%. Investors are also buoyed by the number of investors in a company, with Lyell Immunopharma Inc having a total of 167.0 institutions that hold shares in the company. The top two institutional holders are MWG MANAGEMENT LTD. with over 20.16 million shares worth more than $29.24 million. As of 2024-06-30, MWG MANAGEMENT LTD. held 7.9301% of shares outstanding.
The other major institutional holder is ORLAND PROPERTIES LTD, with the holding of over 15.09 million shares as of 2024-06-30. The firm’s total holdings are worth over $21.89 million and represent 5.9366% of shares outstanding.
